Clinical Research Studies

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Bronchiectasis
• Age: Between 18 years - 99 years
• Gender: Male or Female

• Other Inclusion Criteria:
  

  1. Participants who are 18 years or older
  2. Diagnosed with non–cystic fibrosis bronchiectasis (NCFB)
  3. Participants had at least 2 pulmonary exacerbations requiring oral antibiotics or 1 pulmonary exacerbation requiring intravenous antibiotics
  4. Those who have a documented history of P. aeruginosa infection
  5. Participants had 1 positive sputum culture for P. aeruginosa
  6. Those who are clinically stable and have not required a change in pulmonary treatment
  7. Have pre-bronchodilator FEV =30% of predicted

  
  

You may not be eligible for this study if the following are true:

• 1. Known bronchiectasis as a consequence of cystic fibrosis (CF)
  2. known history of hypogammaglobulinaemia requiring treatment with immunoglobulin, unless fully replaced and considered immuno-competent by the Investigator
  3. Those who have myasthenia gravis or porphyria;
  4. Severe cardiovascular disease
  5. had major surgery in the 3 months
  6. receiving treatment for ABPA
  7. had massive haemoptysis
  8. respiratory failure that would compromise patient safety or confound the evaluation of safety or efficacy of the study in the opinion of the Investigator
  9. current active malignancy, except for basal cell carcinoma or squamous cell carcinoma of the skin without metastases
  10. taking immunosuppressive medications
  11. known history of human immunodeficiency virus (HIV)
  12. current treatment for non-tuberculous mycobacterial (NTM) lung disease or tuberculosis;
  13. known or suspected to be allergic or unable to tolerate colistimethate sodium (intravenous or inhaled) or other polymixins
  14. treatment with long term (= 30 days) prednisone at a dose of greater than 15 mg a day
  15. new maintenance treatment with any oral macrolides
  16. use of any intravenous or intramuscular or oral or inhaled anti-pseudomonal antibiotics
  17. Pregnant or lactating
  18. Significant abnormality in clinical evaluations and/or laboratory tests
  19. Participated in another investigational, interventional trial